Topical and systemic retinoid therapy for cutaneous T-cell lymphoma

Kempf, Werner; Kettelhack, Natascha; Duvic, Madeleine; Burg, Günter

doi:10.1016/s0889-8588(03)00107-2

Cited by 39 publications

(41 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple RAR retinoids have been used in MF/SS, either topically or systemically (reviewed in [222,224]), with response rates exceeding 50%. However, in 1999 the oral RXR-selective ''rexinoid'' bexarotene was FDA approved for CTCL and was later approved as a topical gel formulation.…”

Section: Bexarotenementioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Section: Bexarotenementioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Genetic data also indicate that RXRα are involved in the chemopreventive activity of RA in experimental skin carcinogenesis [10]. It has been reported that targretin, a synthetic RXRα ligand, the major side effect of which is the induction of hypertriglyceridaemia, is recently used for treating persistent or refractory cutaneous T cell lymphoma [9,11,12], indicating the possibility of targeting RXRα for cancer therapy (Table 1). RXRα plays a central role in the regulation of many intracellular receptor signaling pathways and can mediate ligand-dependent transcription.…”

Section: Introductionmentioning

confidence: 99%

The Function of Retinoid X Receptor α in Cancer Cells

Huang¹,

Chen²,

Shen³

2016

Biol syst Open Access

View full text Add to dashboard Cite

The retinoid X receptor (RXR) is a member of the steroid/thyroid hormone superfamily of nuclear receptors (NRs) which are transcription factors that are essential in embryonic development, maintenance of differentiated phenotypes, metabolism and cell death. This review is to provide an overview of the mechanism of RXRα and RXRα signaling pathways involving RXR/TR3, RAR/RXR, PPAR/RXR, VDR/RXR, LXR/RXR, FXR/RXR in cancer cells and other diseases, which will enhance our ability to design rational therapeutic drugs for cancer. Recent studies have shown that an N-terminally truncated RXRα (tRXRα) exists in several cancer cell lines and primary tumors, which is considered as a kind of oncoprotein, demonstrating the new suitability of targeting tRXRα for cancer therapy.

show abstract

“…In the treatment of cancer, the retinoids are considered "biologic response modifiers" (BRMs) in that they are dissimilar to traditional cytotoxic chemotherapy, inducing response without immune suppression, and often augmenting the immune response. [3][4][5] Although there have been a number of clinical studies using retinoids for treatment of breast, ovarian, renal, head and neck, melanoma, and prostate cancers, they are most prominently used in the treatment of hematologic malignancies. In the case of acute promyelocytic leukemia, retinoids in the form of all-trans retinoic acid are used as first-line treatment to restore normal myeloid differentiation to leukemic cells, inducing the formation of mature granulocytes.…”

Section: Introductionmentioning

confidence: 99%

The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

Huen

Kim

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Retinoids are natural and synthetic vitamin A analogs with effects on cell proliferation, differentiation, and apoptosis. They have significant activity in hematologic malignancies and have been studied extensively in cutaneous T-cell lymphoma. Retinoids bind to nuclear receptors and exert their effects through moderation of gene expression. Retinoic acid receptor and retinoic X receptor exert regulatory activity in vivo, binding to distinct ligands. Studies investigating systemic retinoids as monotherapy and in combination with other agents active against cutaneous lymphoma are reviewed. Side effects associated with retinoids include teratogenicity, dyslipidemias, and hypothyroidism, which should be carefully monitored in patients receiving treatment.

show abstract

Topical and systemic retinoid therapy for cutaneous T-cell lymphoma

Cited by 39 publications

References 67 publications

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

The Function of Retinoid X Receptor α in Cancer Cells

The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma

Contact Info

Product

Resources

About